Video: Latest Treatment for Hep C.

Clobetasol Propionate

Pronunciation

Class: Anti-inflammatory Agents
VA Class: DE200
Chemical Name: (11 - β,16β) - 21 - Chloro - 9 - fluoro - 11 - hydroxy - 16 - methyl - 17 - (1 - oxopropoxy) - pregna - 1,4 - diene - 3,20 - dione
Molecular Formula: C25H32ClFO5
CAS Number: 25122-46-7
Brands: Clobevate, Clobex, Cormax, Embeline, Olux, Temovate

Introduction

Synthetic fluorinated corticosteroid.1 80 87 88 89 b c

Uses for Clobetasol Propionate

Corticosteroid-responsive Dermatoses

Short-term relief of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses, including plaque psoriasis and dermatoses of the scalp.1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 32 74 78 80 81 82 83 84 85 86 87 88 89

Slideshow: Psoriasis: Treatment Options to Manage Your Symptoms

Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).a

Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.a

Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.a

Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy.a (See Administration with Occlusive Dressing under Dosage and Administration.)

Response may vary from one topical corticosteroid preparation to another.a

Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.a

Cream, ointment, gel, lotion, shampoo, and foam (0.05% clobetasol propionate) are considered to have high-range potency.1 87 88 a

Not to be used in the treatment of rosacea1 6 18 80 87 89 or perioral dermatitis.1 80 87 89 Topical corticosteroids generally should not be used in the treatment of acne6 18 80 or as monotherapy in the treatment of widespread plaque psoriasis.80

Clobetasol Propionate Dosage and Administration

General

  • Consider location of the lesion and the condition being treated when choosing a dosage form.a

  • Creams are suitable for most dermatoses, but ointments may also provide some occlusion and are usually used for the treatment of dry, scaly lesions.a

  • Lotions are probably best for treatment of weeping eruptions, especially in areas subject to chafing (e.g., axilla, foot, groin).a Lotions, gels, and aerosols may be used on hairy areas, particularly the scalp.a

  • Formulation affects percutaneous penetration and subsequent activity; extemporaneous preparation or dilution of commercially available products with another vehicle may decrease effectiveness.a d

  • Patients applying a topical corticosteroid to a large surface area and/or to areas under occlusion should be evaluated periodically for evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression by appropriate endocrine testing (e.g., ACTH stimulation, plasma cortisol, urinary free cortisol).1 88 a (See Hypothalamic-Pituitary-Adrenal Axis Suppresion and also Systemic Effects, under Cautions.)

Administration

Topical Administration

For dermatologic use only; avoid contact with eyes.1 If such contact occurs, flush affected eye(s) with copious amounts of water.80 81 82 83

Do not apply to the face or intertriginous areas (e.g., axilla, groin).1 87 88 89

Cream, ointment, gel, or solution containing clobetasol propionate not intended for ophthalmic, oral, or intravaginal use.1 80 87

The area of skin to be treated may be thoroughly cleansed before topical application to reduce the risk of infection; however, some clinicians believe that, unless an occlusive dressing is used, cleansing of the treated area is unnecessary and may be irritating.a

Apply cream, ointment, gel, lotion, or foam sparingly in a thin film and rub gently into affected area.1 80 88 89 b

To apply foam, invert canister; dispense a small amount (up to a maximum of a golf-ball-sized dollop or 1 1/2 capfuls) of foam into the cap of the canister, onto cool surface (e.g., saucer), or directly on the lesion, taking care to avoid contact with the eyes.88 Foam will begin to melt immediately upon contact with warm skin; do not dispense directly onto hands (unless the hands are the affected area).88 If the canister seems warm to the touch or the foam seems runny, place the canister under cold running tap water.88 Using clean, dry fingertips, gently massage foam into the affected area; repeat until the entire affected area has been treated.88 Avoid exposure to flames or smoking during and immediately after application.88

Apply solution to affected areas of the scalp.80 81 84

Apply shampoo onto dry scalp; leave for 15 minutes before washing and rinsing; avoid contact with lips.c

After a favorable response is achieved, frequency of application may be decreased to the minimum necessary to maintain control and to avoid relapse; discontinue if possible.a

Administration with Occlusive Dressing

Manufacturers state that the cream, gel, ointment, or solution should not be used with occlusive dressings.1 80 87 89 However, when appropriate, occlusive dressings may be used as directed by a clinician to augment efficacy of lotion, shampoo, or foam preparations.88 b c (See Occlusive Dressings under Cautions.)

Soak or wash the affected area to remove scales; apply a thin film of the corticosteroid preparation; rub gently into the lesion; and apply another thin film.a Cover affected area with a thin, pliable plastic film and seal it to adjacent normal skin with adhesive tape or hold in place with a gauze or elastic bandage.a

If affected area is moist, incompletely seal the edges of the plastic film or puncture the film to allow excess moisture to escape.a For added moisture in dry lesions, apply the corticosteroid preparation and cover with a dampened cloth before the plastic film is applied or briefly soak the affected area in water before application of the drug and plastic film.a

Thin polyethylene gloves may be used on the hands and fingers, plastic garment bags may be used on the trunk or buttocks, a tight shower cap may be used for the scalp, or whole-body suits may be used instead of plastic film to provide occlusion.a

Frequency of occlusive dressing changes depends on the condition being treated; cleansing of the skin and reapplication of clobetasol proprionate are essential at each dressing change.a

Occlusive dressing usually is left in place for 12–24 hours and therapy is repeated as needed.a Although occlusive dressing may be left in place for 3–4 days at a time in resistant conditions, most clinicians recommend intermittent use of occlusive dressings for 12 hours daily to reduce the risk of adverse effects (particularly infection) and systemic absorption and for greater convenience.a

The drug and an occlusive dressing may be used at night, and the drug or a bland emollient may be used without an occlusive dressing during the day.a

In patients with extensive lesions, sequential occlusion of only one portion of the body at a time may be preferable to whole-body occlusion.a (See Occlusive Dressings under Cautions.)

Dosage

Available as clobetasol propionate; dosage expressed in terms of the salt.1 80 87 88 89 b c

Intermittent maintenance therapy, such as administration of the drug once12 or twice weekly20 21 for up to 6 months, has resulted in prolonged periods of remission from corticosteroid-responsive dermatoses in some patients.12 20 21

Pediatric Patients

Administer the least amount of topical preparations that provides effective therapy.a (See Pediatric Use under Cautions.)

Corticosteroid-responsive Dermatoses
Topical

Children ≥12 years of age: Apply cream, ointment, gel, foam, or solution sparingly to affected area twice daily, preferably in the morning and evening.1 80 81 84 87 88 89

Discontinue when control is achieved; if improvement does not occur within 2 weeks, consider reassessment of the diagnosis.1 87 89

Adults

Corticosteroid-responsive Dermatoses
Topical

Apply cream, ointment, gel, lotion, foam, or solution sparingly to affected area twice daily, preferably in the morning and evening.1 80 81 84 87 88 89 b

Discontinue when control is achieved; if improvement does not occur within 2 weeks, consider reassessment of the diagnosis.1 87 89

Emollient cream or lotion (applied to no more than 10% of body surface area) may be used for up to 4 consecutive weeks in the management of plaque psoriasis; however, the manufacturers state that additional benefits of extended treatment (i.e., >2 weeks) should be weighed against the risk of HPA-axis suppression.89 b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)

Apply shampoo to scalp once daily.c Discontinue when control is achieved.c If improvement does not occur within 4 weeks, consider reassessment of the diagnosis and consider substituting a less potent topical corticosteroid preparation.c

Prescribing Limits

Pediatric Patients

Corticosteroid-responsive Dermatoses
Topical

Maximum 50 g of 0.05% cream, ointment, or gel per week for no more than 2 consecutive weeks.1 87 88 89

Maximum 1 1/2 capfuls of foam per application; maximum 50 g per week for no more than 2 consecutive weeks.88

Maximum 50 mL (50 g) of 0.05% solution per week for no more than 2 consecutive weeks.80

Adults

Corticosteroid-responsive Dermatoses
Topical

Maximum 50 g of 0.05% cream, ointment, gel, or lotion per week for no more than 2 consecutive weeks.1 87 88 89 b

Maximum 1 1/2 capfuls of foam per application; maximum 50 g per week for no more than 2 consecutive weeks.88

Maximum 50 mL (50 g) of 0.05% solution per week for no more than 2 consecutive weeks.80

In patients with plaque psoriasis, maximum 50 g of 0.05% emollient cream, shampoo, or lotion per week for no more than 4 consecutive weeks.89 b

In patients with psoriasis of the scalp, maximum 4 consecutive weeks of therapy with shampoo.c

Special Populations

Geriatric Patients

No dosage adjustments with cream, ointment, gel, or solution.1 80 87 89 Titrate dosage carefully when using foam, lotion, or shampoo; initiate therapy at the low end of the dosage range.88 b c

Cautions for Clobetasol Propionate

Contraindications

  • Known hypersensitivity to clobetasol propionate, other corticosteroids, or any ingredient in the formulation.1 80 87 88 89

  • Primary infections of the scalp (clobetasol propionate solution).80

Warnings/Precautions

Sensitivity Reactions

Allergic contact dermatitis may manifest as failure to heal rather than irritation as occurs with other topical preparations that do not contain corticosteroids; confirm with diagnostic patch testing.1 87 89 b c

Major Toxicities

Risk of Systemic Effects with Highly Active Preparations

Clobetasol propionate is a potent topical corticosteroid and can be absorbed in sufficient amounts to produce systemic effects, including HPA-axis suppression.1 3 7 11 12 13 17 18 19 20 26 27 56 55 59 61 62 64 76 80 87 88 89 b c (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)

General Precautions

Hypothalamic-Pituitary-Adrenal Axis Suppression.

Topically applied corticosteroids can be absorbed in sufficient amounts to reversibly suppress the HPA axis.1 3 7 11 12 13 17 18 19 20 26 27 46 55 57 59 61 62 64 76 80 87 88 89 b c HPA-axis suppression has occurred following topical dosages as low as 2 g of the 0.05% ointment or cream (1 mg of clobetasol propionate total) or 7 g of the 0.05% foam (3.5 mg of clobetasol propionate total) daily.1 76 88

Perform periodic HPA-axis evaluation by appropriate testing (e.g., ACTH stimulation, morning plasma cortisol, urinary free cortisol), especially in patients applying a topical corticosteroid to a large surface area or to areas under occlusion.1 80 87 88 89 b c

If HPA-axis suppression occurs, withdraw the drug, reduce the frequency of application, and/or substitute a less potent corticosteroid.1 a

HPA-axis function recovery generally is prompt and complete following drug discontinuance.1 a

Rarely, glucocorticosteroid insufficiency may require systemic corticosteroid therapy.1 a

Systemic Effects

Systemic absorption following topical administration may result in manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.a

Risk of adverse systemic effects increases with use of a high-potency topical corticosteroid, especially if applied to large areas of the body, for prolonged periods of time, with an occlusive dressing, and/or concurrently with other corticosteroid-containing preparations.a

Infants and children may be more susceptible to adverse systemic effects.87 88 89 d (See Pediatric Use under Cautions.)

Local Effects

Possible adverse local reactions (e.g., irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, miliaria); may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.1 87 88 89 b c

Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue;a these effects are most likely to occur (even with short-term use) in intertriginous (e.g., axilla, groin), flexor, and facial areas.a Do not apply to the face or intertriginous areas.1 87 88 89

If irritation occurs during treatment, discontinue drug and institute appropriate therapy.1 80 87 88 89 b c

Skin Infections

If concurrent skin infection is present or develops, initiate appropriate anti-infective therapy.1 87 88 89 b c If infection does not respond promptly, discontinue topical corticosteroid therapy until the infection has been controlled.1 87 88 89 b c

When topical corticosteroids and topical anti-infectives are used concomitantly, consider that the corticosteroid may mask clinical signs of bacterial, fungal, or viral infections; prevent recognition of ineffectiveness of the anti-infective; or suppress hypersensitivity reactions to ingredients in the formulation.a d In addition, consider the cautions, precautions, and contraindications associated with the anti-infective.a d

Do not use occlusive dressings in patients with primary skin infection.d

Some manufacturers state that topical corticosteroids are contraindicated in patients with tuberculosis of the skin, dermatologic fungal infections, and cutaneous or systemic viral infection (including vaccinia and varicella and herpes simplex of the eye or adjacent skin);a however, most clinicians believe topical corticosteroids can be used with caution if the infection is treated.a

Occlusive Dressings

Certain topical clobetasol propionate preparations (cream, gel, ointment, solution) should not be used with occlusive dressings.1 80 87 89

Adverse systemic corticosteroid effects may occur with use of occlusive dressings on large areas of the body and for prolonged periods of time; monitor accordingly.1 88 a (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)

Adverse local reactions may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.1 88 a b c (See Local Effects under Cautions.)

Do not use occlusive dressings on weeping or exudative lesions.a

Do not use occlusive dressings in patients with primary skin infection.a

Remove occlusive dressings covering large areas if body temperature increases; thermal homeostasis may be impaired.a

Use plastic occlusive material with care to avoid the risk of suffocation.a

Specific Populations

Pregnancy

Category C.1 80 87 88 89 b c

Lactation

Not known whether topical clobetasol is distributed into milk.1 80 87 88 89 b c Caution advised if topical clobetasol is used.1 80 87 88 89 b c

Pediatric Use

Use of clobetasol propionate cream, ointment, solution, foam, or gel not recommended in children <12 years of age.1 80 87 88

Use of clobetasol propionate lotion or shampoo not recommended in children <18 years of age.b c

Use of clobetasol propionate emollient cream not recommended in children <12 years of age; use beyond 2 consecutive weeks has not been evaluated in children <16 years of age.89

Children are more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing’s syndrome than mature individuals because of a greater skin surface area-to-body weight ratio,1 80 87 88 89 b c especially when topical corticosteroids are applied to >20% of body surface area.a The risk of adrenal suppression appears to increase with decreasing age.a (See Systemic Effects under Cautions.)

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation.1 80 87 88 89 a b c a

Children also are at greater risk of glucocorticosteroid insufficiency during and/or after withdrawal of treatment.a

Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema.1 80 87 88 89 a b c a

Striae have been reported in children treated inappropriately with topical corticosteroids.1 87 88 89 a b c

Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic effect; chronic topical corticosteroid therapy may interfere with growth and development.d

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether safety and efficacy of clobetasol propionate cream, ointment, gel, foam, lotion, or solution in geriatric patients differ from safety and efficacy in younger adults.1 80 87 88 89 b c

Common Adverse Effects

Burning, stinging, irritation, itching, skin atrophy, dry skin, cracking or fissuring of the skin, erythema, folliculitis, numbness of fingers, tenderness in the elbow, telangiectasia.1 80 88 89 a b c

Clobetasol propionate solution or shampoo: pustules on the scalp, tingling, folliculitis, tightening of the scalp, tenderness, dermatitis (e.g., irritant), urticaria, edema, acne, alopecia, headache.80 c

Interactions for Clobetasol Propionate

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Corticosteroids

Potential pharmacologic interaction with other corticosteroid-containing preparationsa

Nitroblue-tetrazolium test for bacterial infection

Concurrent use of corticosteroids reportedly may result in false-negative resultsa

Clobetasol Propionate Pharmacokinetics

Absorption

Bioavailability

Topically applied clobetasol propionate can be absorbed through normal intact skin.1 80 87 88 a b c

Percutaneous penetration of clobetasol propionate varies among individuals5 33 34 35 41 42 61 66 67 69 70 and can be altered by using different vehicles.1 7 18 22 30 31 41 43 67 69 71 73 80 87 88 89 b c

Percutaneous penetration can be increased by use of occlusive dressings and by presence of inflammation and/or other disease of the epidermal barrier (e.g., psoriasis, eczema).1 80 87 88 a b c

Distribution

Extent

Not known whether topical clobetasol is distributed into milk.1 80 87 88 89 b c

Elimination

Metabolism

Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver.80 88 b

Elimination Route

Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in bile.80 88 b

Stability

Storage

Topical

Cream or Ointment

15–30°C; the cream should not be refrigerated.1 89

Gel

2–30°C.87

Solution

4–25°C; the solution should not be used near an open flame.80

Foam

20–25°C; exposure to temperatures >49°C should be avoided.88 The container should not be punctured, used or stored near heat or an open flame, or placed into a fire or incinerator for disposal.88

Keep out of reach of children.88

Lotion

20–25°; freezing should be avoided.b

Shampoo

Tight containers at 20–25°.c

Actions

  • High-range corticosteroid activity.1 87 88 a b c

  • Produces anti-inflammatory, antipruritic, and vasoconstrictor actions, possibly resulting in part from steroid receptor binding.a

  • Precise mechanism of action for topical anti-inflammatory activity is unknown; therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions.1 80 87 88 89 b c

  • Anti-inflammatory effects may occur through induction of phospholipase A2 inhibitory proteins (lipocortins); decreased arachidonic acid release from membrane phospholipids.1 87 88 89 b c Decreased arachidonic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes).1 87 88 89 b c

Advice to Patients

  • Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed.1 80 87 88 89 a b c (See Topical Administration under Dosage and Administration.)

  • Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician.1 80 87 88 89 a c

  • Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to a clinician.1 80 87 88 89 b

  • Importance of patients informing clinician that they are receiving topical clobetasol propionate therapy, if surgery is contemplated.87 89 b c

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 80 87 88 89 b c

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1 80 87 88 89 b c

  • Importance of informing patients of other important precautionary information.1 80 87 88 89 b c (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Clobetasol Propionate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Aerosol, foam suspension

0.05%

Olux (with alcohol 60%, propylene glycol, and propane/butane propellant)

Connetics

Cream

0.05%*

Clobetasol Propionate Cream

Alpharma, Fougera, Taro

Clobetasol Propionate Cream (Emollient)

Fougera, Taro

Cormax (with propylene glycol and parabens)

Watson

Embeline E (with propylene glycol)

Healthpoint

Temovate (with propylene glycol)

GlaxoSmithKline

Temovate E (with propylene glycol)

GlaxoSmithKline

Gel

0.05%*

Clobetasol Propionate Gel

Fougera, Glades, Taro

Clobevate (with propylene glycol)

Stiefel

Temovate (with propylene glycol)

GlaxoSmithKline

Lotion

0.05%

Clobex (with propylene glycol)

Galderma

Ointment

0.05%*

Clobetasol Propionate Ointment

Alpharma, Fougera, Taro

Cormax (with propylene glycol)

Watson

Temovate (with propylene glycol)

GlaxoSmithKline

Shampoo

0.05%

Clobex (with alcohol)

Galderma

Solution

0.05%*

Clobetasol Propionate Solution

Fougera, Taro

Cormax Scalp Application (with isopropyl alcohol 40% w/w)

Watson

Embeline

Healthpoint

Temovate Scalp Application (with isopropyl alcohol 39.3%)

GlaxoSmithKline

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Clobetasol Propionate 0.05% Cream (FOUGERA): 30/$17.99 or 90/$44.99

Clobetasol Propionate 0.05% Cream (TARO): 45/$29.99 or 135/$85.16

Clobetasol Propionate 0.05% Cream (TARO): 60/$39.99 or 180/$111.96

Clobetasol Propionate 0.05% Foam (PERRIGO PHARMACEUTICALS): 50/$119.99 or 150/$309.98

Clobetasol Propionate 0.05% Foam (PERRIGO PHARMACEUTICALS): 100/$229.99 or 300/$639.96

Clobetasol Propionate 0.05% Gel (FOUGERA): 15/$25.99 or 45/$59.97

Clobetasol Propionate 0.05% Gel (FOUGERA): 30/$29.99 or 90/$69.98

Clobetasol Propionate 0.05% Gel (FOUGERA): 60/$42.99 or 180/$121.96

Clobetasol Propionate 0.05% Ointment (FOUGERA): 30/$14.99 or 90/$41.97

Clobetasol Propionate 0.05% Ointment (TARO): 45/$38.99 or 135/$112.98

Clobetasol Propionate 0.05% Ointment (TARO): 60/$40.99 or 180/$114.96

Clobetasol Propionate 0.05% Solution (TARO): 25/$31.19 or 75/$86.35

Clobetasol Propionate 0.05% Solution (TARO): 50/$59.99 or 150/$165.97

Clobetasol Propionate E 0.05% Cream (TARO): 15/$23.99 or 30/$38.97

Clobetasol Propionate E 0.05% Cream (TARO): 60/$35.99 or 180/$89.98

Clobex 0.05% Lotion (GALDERMA): 59/$318.53 or 177/$931.86

Clobex 0.05% Lotion (GALDERMA): 118/$575.89 or 354/$1,603.84

Clobex 0.05% Shampoo (GALDERMA): 118/$423.01 or 354/$1,241.89

Clobex Spray 0.05% Liquid (GALDERMA): 59/$274.99 or 177/$800.98

Clobex Spray 0.05% Liquid (GALDERMA): 125/$503.99 or 375/$1,470.02

Olux 0.05% Foam (GLAXO SMITH KLINE): 50/$239.06 or 150/$709.44

Olux 0.05% Foam (GLAXO SMITH KLINE): 100/$456.00 or 300/$1,330.04

Olux-E 0.05% Foam (GLAXO SMITH KLINE): 50/$203.68 or 100/$385.14

Olux-E 0.05% Foam (GLAXO SMITH KLINE): 100/$388.98 or 300/$1,121.93

Temovate 0.05% Cream (PHARMADERM): 30/$126.98 or 90/$359.95

Temovate 0.05% Cream (PHARMADERM): 60/$262.00 or 180/$755.98

Temovate 0.05% Gel (PHARMADERM): 60/$205.99 or 120/$411.99

Temovate 0.05% Ointment (PHARMADERM): 15/$93.99 or 45/$240.97

Temovate 0.05% Ointment (PHARMADERM): 30/$152.99 or 90/$434.99

Temovate 0.05% Solution (PHARMADERM): 50/$190.98 or 150/$555.96

Temovate E 0.05% Cream (PHARMADERM): 60/$213.98 or 180/$602.96

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions July 1, 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. GlaxoSmithKline. Temovate (clobetasol propionate) cream 0.05% and ointment 0.05% prescribing information. Pittsburgh, PA; 2002 Aug.

2. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 28th ed. London: The Pharmaceutical Press; 1982:463-4.

3. Allenby CF, Main RA, Marsden RA et al. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J. 1975; 4:619-21. [IDIS 60244] [PubMed 1203701]

4. Mahood JM. Familial lichen planus: a report of nine cases from four families with a brief review of the literature. Arch Dermatol. 1983; 119:292-4. [IDIS 168707] [PubMed 6838234]

5. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984; 120:631-5. [IDIS 184537] [PubMed 6721525]

6. Woodbridge P. The use of a new topical steroid in general practice. Practitioner. 1974; 212:732-6. [IDIS 42392] [PubMed 4282417]

7. Sneddon IB. Clinical use of topical corticosteroids. Drugs. 1976; 11:193-9. [IDIS 69127] [PubMed 776579]

8. Marks JM. Psoriasis: utilising the treatment options. Drugs. 1980; 19:429-36. [IDIS 115824] [PubMed 6446452]

9. Naysmith A, Hancock BW. Hodgkin’s disease and pemphigus. Br J Dermatol. 1976; 94:695-6. [IDIS 74965] [PubMed 949462]

10. Lane P. Transient acantholytic dermatosis in South Africa. Arch Dermatol. 1977; 113:982. [IDIS 90238] [PubMed 879821]

11. Staughton RCD, August PJ. Cushing’s syndrome and pituitary-adrenal suppression due to clobetasol propionate. Br Med J. 1975; 2:419-21. [IDIS 52665] [PubMed 1125562]

12. Hradil E, Lindström C, Möller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol (Stockh). 1978; 58:375-8.

13. Walker SR, Wilson L, Fry L et al. The effect on plasma corticosteroid levels of the short term topical application of clobetasol propionate. Br J Dermatol. 1974; 91:339-43. [IDIS 46959] [PubMed 4447661]

14. Clayton R. A double-blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol. 1977; 96:71-3. [IDIS 88041] [PubMed 320996]

15. Gould PW, Wilson L. Psoriasis treated with clobetasol propionate and photochemotherapy. Br J Dermatol. 1978; 98:133-6. [IDIS 94625] [PubMed 343806]

16. Wendt H, Mugglestone CJ, Wiseman RA. A study of the comparative efficacy of diflucortolone valerate 0.3% ointment and clobetasol propionate 0.05% ointment. Br J Dermatol. 1978; 99:411-6. [IDIS 118175] [PubMed 361059]

17. Keczkes K, Teasdale P, Wiseman RA et al. Plasma cortisol values after topical application of diflucortolone valerate (0.3%) or clobetasol propionate (0.05%) in psoriatic patients. Br J Dermatol. 1978; 99:417-20. [IDIS 118176] [PubMed 361060]

18. Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatol Clin. 1984; 2:397-409.

19. Jegasothy B, Jacobson C, Levine N et al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol. 1985; 24:461-5. [PubMed 3902682]

20. Svartholm H, Larsson L, Frederiksen B. Intermittent topical treatment of psoriasis with clobetasol propionate (’Dermovate’). Curr Med Res Opin. 1982; 8:154-7. [PubMed 6751703]

21. Möller H, Svartholm H, Dahl G. Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and flupredniden acetate. Curr Med Res Opin. 1983; 8:640-4. [PubMed 6365465]

22. Sparkes CG, Wilson L. The clinical evaluation of a new topical corticosteroid, clobetasol propionate: an international controlled trial. Br J Dermatol. 1974; 90:197-203. [IDIS 47616] [PubMed 4594577]

23. Stankler L. A double-blind comparison of quarter strength clobetasol propionate in unguentum Merck with betamethasone valerate in psoriasis. Br J Clin Pract. 1983; 37:389-91. [IDIS 181739] [PubMed 6367795]

24. Floden CH, Woodbridge P, Samman P et al. Comparison of the response of psoriasis, over a 6-month period, to clobetasol propionate and fluocinolone acetonide ointments. Curr Med Res Opin. 1975; 3:375-81. [PubMed 1183219]

25. Hindson TC, Spiro J, Scott LV. Clobetasol propionate ointment reduces inflammation after cryotherapy. Br J Dermatol. 1985; 112:599-602. [IDIS 201263] [PubMed 3890918]

26. Gip L, Hamfelt A. A double-blind clinical trial of Diprolene ointment versus Dermovate ointment for resistant psoriasis and atopic dermatoses. Curr Ther Res. 1981; 30:895-904.

27. Gip L, Hamfelt A. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses. Cutis. 1984; 33:215-7,220-2,224. [PubMed 6365474]

28. Verdich J, Karlsmark T. Betamethasone dipropionate cream for the treatment of psoriasis: a double-blind comparison with clobetasol propionate cream. Dermatologica. 1985; 170:152-5. [PubMed 3979642]

29. Harst LCA, de Jonge H, Pot F et al. Comparison of two application schedules for clobetasol 17 propionate. Acta Derm Venereol (Stockh). 1982; 62:270-3.

30. Finlay AY, Watson WS. Stratum corneum penetration kinetics of clobetasol 17-propionate in vivo: the effect of different bases. Br J Dermatol. 1985; 113:791.

31. Woodford R. Investigation of the release characteristics of unguentum Merck as a diluent for topical corticosteroid preparations. Curr Ther Res. 1981; 29:17-23.

32. Voigtlander V. A clinical comparison of betamethasone 17,21-dipropionate and clobetasol propionate creams in dermatology. J Int Med Res. 1977; 5:128-31. [PubMed 326594]

33. Crijns MB, Nater JP, van Oostveen F et al. Vasoconstrictor and the anti-inflammatory effects of 7 corticosteroids. Contact Dermatitis. 1984; 11:108-11. [PubMed 6488765]

34. Kirsch J, Gibson JR, Darley CR et al. A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasoconstrictor assay. Dermatologica. 1983; 167:138-41. [PubMed 6195026]

35. Barry BW, Woodford R. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels. Br J Dermatol. 1974; 91:323-38. [IDIS 46958] [PubMed 4611447]

36. Parish LC, Witkowski JA, Muir JG. Topical corticosteroids. Int J Dermatol. 1985; 24:435-6. [PubMed 4055197]

37. Woodford R, Haigh JM. Bioavailability and activity of 0.1% amcinonide preparations: comparison with proprietary topical corticosteroid formulations of differing potencies. Curr Ther Res. 1979; 26:301-10.

38. Barry BW, Woodford R. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments. Br J Dermatol. 1975; 93:563-71. [IDIS 63141] [PubMed 1203181]

39. Gaillard RC, Poffet D, Riondel AM et al. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab. 1985; 61:1009-11. [IDIS 208819] [PubMed 4055982]

40. Poelman MC, Leveque JL, Le Gall F. Objective determination of the bioavailability of dermocorticoids—influence of the formulation. Br J Dermatol. 1984; 111(Suppl 27):158-62. [IDIS 188322] [PubMed 6743548]

41. Gibson JR, Kirsch JM, Darley CR et al. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol. 1984; 111(Suppl 27):204-12. [IDIS 188324] [PubMed 6378245]

42. Feather JW, Ryatt KS, Dawson JB et al. Reflectance spectrophotometric quantification of skin colour changes induced by topical corticosteroid preparations. Br J Dermatol. 1982; 106:437-44. [IDIS 150389] [PubMed 7073967]

43. Gibson JR, Darley C, Kirsch J et al. The dilution of proprietary corticosteroid ointments—an attempt to evaluate relative clinical potencies. Br J Dermatol. 1982; 106:445-8. [IDIS 150390] [PubMed 7073968]

44. Gibson JR, Kirsch J, Darley CR et al. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations. Br J Dermatol. 1983; 109:114-6. [IDIS 173531] [PubMed 6860578]

45. Farber EM, Nall L. Psoriasis: a review of recent advances in treatment. Drugs. 1984; 28:324-6. [IDIS 193571] [PubMed 6386427]

46. Carruthers JA. The use of Dermovate in the treatment of psoriasis. Can Med Assoc J. 1978; 119:563-4. [IDIS 87062] [PubMed 709447]

47. Dooms-Goossens A, Vanhee J, Vanderheyden D et al. Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasone butyrate. Contact Dermatitis. 1983; 9:470-8. [PubMed 6653104]

48. Chalmers RJG, Beck MH, Muston HL. Simultaneous hypersensitivity to clobetasone butyrate and clobetasol propionate. Contact Dermatitis. 1983; 9:317-8. [PubMed 6225613]

49. Boyle J, Peachey RDG. Allergic contact dermatitis to Dermovate and Eumovate. Contact Dermatitis. 1984; 11:50-1. [PubMed 6235094]

50. van Ketel WG, Swain AF. Allergy to clobetasol-17-propionate (Dermovate). Contact Dermatitis. 1981; 7:278-9. [PubMed 7307491]

51. Bachmann-Buffle B. Allergy to clobetasol-17-propionate (Dermovate). Dermatologica. 1983; 167:104. [PubMed 6628801]

52. Cotterill JA. Perioral dermatitis. Br J Dermatol. 1979; 101:259-62. [IDIS 101943] [PubMed 159712]

53. Wilkinson DS, Kirton V, Wilkinson JD. Perioral dermatitis: a 12-year review. Br J Dermatol. 1979; 101:245-57. [IDIS 101942] [PubMed 159711]

54. Zheng P, Lavker RM, Lehmann P et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol. 1984; 82:345-52. [IDIS 183980] [PubMed 6368701]

55. Miyachi Y. Adrenal axis suppression caused by a small dose of a potent topical corticosteroid. Arch Dermatol. 1982; 118:451-2. [IDIS 153282] [PubMed 7092266]

56. Boxley JD, Dawber RPR, Summerly R. Generalized pustular psoriasis on withdrawal of clobetasol propionate ointment. Br Med J. 1975; 2:255-6. [IDIS 52730] [PubMed 1131576]

57. Ortega E, Burdick KH, Segre EJ. Adrenal suppression by clobetasol propionate. Lancet. 1975; 1:1200. [IDIS 52175] [PubMed 48826]

58. Hardie RA, Waring AJ, Barnetson RS. Atrophic skin striae following the use of clobetasol propionate ointment. Practitioner. 1977; 219:376-8. [IDIS 85328] [PubMed 928283]

59. Nathan AW, Rose GL. Fatal iatrogenic Cushing’s syndrome. Lancet. 1979; 1:207. [IDIS 91472] [PubMed 84219]

60. Tan CY, Marks R, Payne P. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol. 1981; 76:126-8. [IDIS 138129] [PubMed 7462674]

61. Carruthers JA, August PJ, Staughton RCD. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J. 1975; 4:203-4. [IDIS 59737] [PubMed 1191997]

62. Carruthers JA, Staughton RCD, August PJ. Penetration of topical steroid preparations. Arch Dermatol. 1977; 113:522. [IDIS 84842] [PubMed 848992]

63. Feiwel M, Kelly WF. Adrenal unresponsiveness associated with clobetasol propionate. Lancet. 1974; 2:112-3. [IDIS 42743] [PubMed 4136855]

64. Stoppoloni G, Prisco F, Santinelli R et al. Potential hazards of topical steroid therapy. Am J Dis Child. 137; 1130-1. Letter. (IDIS 177573)

65. Frosch PJ, Behrenbeck EM, Frosch K et al. The Duhring chamber assay for corticosteroid atrophy. Br J Dermatol. 1981; 104:57-65. [IDIS 129688] [PubMed 7459270]

66. Hehir M, Du Vivier A, Eilon L et al. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol. 1983; 8:143-51. [PubMed 6851236]

67. Harding SM, Sohail S, Busse MJ. Percutaneous absorption of clobetasol propionate from novel ointment and cream formulations. Clin Exp Dermatol. 1985; 10:13-21. [PubMed 3987081]

68. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962; 86:608-10.

69. Maibach HI. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica. 1976; 152(Suppl 1):11-25. [PubMed 955232]

70. Pascher F. Systemic reactions to topically applied drugs. Drug Ther. 1976; 6:125-30.

71. Polano MK, Ponec M. Dependence of corticosteroid penetration on the vehicle. Arch Dermatol. 1976; 112:675-80. [PubMed 1275523]

72. Scoggins RB, Kliman B. Percutaneous absorption of corticosteroids. N Engl J Med. 1965; 273:831-40. [PubMed 5825903]

73. Wilson L. The clinical assessment of topical corticosteroid activity. Br J Dermatol. 1976; 94(Suppl 12):33-42. [IDIS 69132] [PubMed 773412]

74. Corbett MF. The response of psoriasis to betamethasone valerate and clobetasol propionate: a 6-month controlled study. Br J Dermatol. 1976; 94(Suppl 12):89-93. [IDIS 69140] [PubMed 773414]

75. Richards RN. Clinical experience with 0.05% clobetasol propionate creams. J Am Acad Dermatol. 1985; 12:891-3. [PubMed 4008693]

76. Vonderweidt J (Glaxo Inc, Research Triangle Park, NC); personal communication.

77. Reviewers’ comments (personal observations).

78. Jacobson C, Cornell RC, Savin RC. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis. 1986; 37:213-20. [PubMed 3514155]

79. Hogan DJ, Sibley JT, Lane PR. Avascular necrosis of the hips following long-term use of clobetasol propionate. J Am Acad Dermatol. 1986; 14:515-6. [PubMed 3958267]

80. GlaxoSmithKline. Temovate (clobetasol propionate) scalp application 0.05% prescribing information. Pittsburgh, PA; 2002 Aug.

81. Olsen EA, Cram DL, Ellis CN et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991; 24:443-7. [PubMed 2061442]

82. Hillström L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp. J Int Med Res. 1982; 10:419-22. [PubMed 7152080]

83. Ishibashi Y, Koe M, Iwata J et al. Derumobeto sukarupu no tobu shirosei hifer ni taisuru rinsho kota. (Japanese; translation supplied by Glaxo Dermatology.) Nishinippon Hifuka. 1987; 49:126-30.

84. Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate in alcoholic solution: a comparison of once and twice a day application. Curr Med Res Opin. 1976; 4:214-7. [PubMed 949901]

85. Zar E. Topical clobetasol propionate in the treatment of scalp psoriasis: a medium term follow-up. Curr Ther Res. 1980; 28:997-1001.

86. Roduner J, Krebs A. [Dermovate scalp application in dermatologic practice: a multi-centre study covering the whole of Switzerland.] (German; translation supplied by Glaxo Dermatology.) Ther Umsch. 1980; 37:589-94.

87. GlaxoSmithKline. Temovate (clobetasol propionate) gel 0.05% prescribing information. Pittsburg, PA; 2002 Aug.

88. Connetics Corporation. Olux foam 0.05% (clobetasol propionate) prescribing information. Palo Alto, CA; 2003 Jun.

89. GlaxoSmithKline. Temovate E (clobetasol propionate) emollient cream. Research Triangle Park, NC; 2000 Jul.

a. AHFS drug information 2005 McEvoy GK, ed. Topical Corticosteroids General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2005:3425-8.

b. Galderma. Clobex (clobetasol propionate) lotion 0.05% prescribing information. San Antonio, TX; 2003 Jul.

c. Galderma. Clobex (clobetasol propionate) shampoo 0.05% prescribing information. San Antonio, TX; 2004 Jan.

d. AHFS drug information 2006. McEvoy GK, ed. Neomycin Sulfate. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 2739-40.

Hide
(web3)